Critical Survey: ImmunoGen (IMGN) vs. Its Rivals
ImmunoGen (NASDAQ: IMGN) is one of 198 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its peers? We will compare ImmunoGen to similar companies based on the strength of its risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.
Risk & Volatility
ImmunoGen has a beta of 2.36, indicating that its stock price is 136% more volatile than the S&P 500. Comparatively, ImmunoGen’s peers have a beta of 1.63, indicating that their average stock price is 63% more volatile than the S&P 500.
This table compares ImmunoGen and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
72.9% of ImmunoGen shares are held by institutional investors. Comparatively, 46.8% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 6.5% of ImmunoGen shares are held by company insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a breakdown of recent ratings for ImmunoGen and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ImmunoGen currently has a consensus target price of $8.05, suggesting a potential upside of 41.48%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.67%. Given ImmunoGen’s higher possible upside, analysts plainly believe ImmunoGen is more favorable than its peers.
Valuation and Earnings
This table compares ImmunoGen and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|ImmunoGen||$83.41 million||-$69.45 million||-4.74|
|ImmunoGen Competitors||$207.79 million||-$2.30 million||2.07|
ImmunoGen’s peers have higher revenue and earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
ImmunoGen peers beat ImmunoGen on 7 of the 12 factors compared.
ImmunoGen Company Profile
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.
Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.